Malignant Mesothelioma: Time to Translate?

Trends in Cancer

Volumn 2, Issue 9, 2016, Pages 467-474

  Napolitano, Andrea ^a   Carbone, Michele ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

BAP1; malignant mesothelioma; therapy; translation

Indexed keywords

AMATUXIMAB; ASBESTOS; BEVACIZUMAB; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CANCER VACCINE; CARCINOGEN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKINE; FOCAL ADHESION KINASE; FOLIC ACID ANTAGONIST; GROWTH FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; MAMMALIAN TARGET OF RAPAMYCIN; MESOTHELIN; MINERAL FIBER; ONCOLYTIC VIRUS; PEMETREXED; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN P53; RAPAMYCIN; TICILIMUMAB; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR YAP1; TUMOR ANTIGEN; TUMOR MARKER; UNINDEXED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DRUG TARGETING; GENETIC RISK; GENOME ANALYSIS; GERMLINE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; MESOTHELIOMA; MESOTHELIUM CELL; MOLECULAR BIOLOGY; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; ANIMAL; GENETICS; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; TRANSLATIONAL RESEARCH;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MOLECULAR TARGETED THERAPY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84989869556     PISSN: 24058033     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trecan.2016.07.004     Document Type: Review

References (76)

1. 1 Carbone, M., et al. Malignant mesothelioma: facts, myths, and hypotheses. J. Cell. Physiol. 227 (2012), 44–58.
2. 2 Henley, S.J., et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int. J. Occup. Environ. Health 19 (2013), 1–10.
3. 3 Carbone, M., Yang, H., Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma. Clin. Cancer Res. 18 (2012), 598–604.
4. 4 Sluis-Cremer, G.K., et al. The mortality of amphibole miners in South Africa, 1946-80. Br. J. Ind. Med. 49 (1992), 566–575.
5. 5 Bononi, A., et al. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev. Respir. Med. 9 (2015), 633–654.
6. 6 Carbone, M., et al. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J. Thorac. Oncol. 11 (2016), 1246–1262.
7. 7 Treasure, T., et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 12 (2011), 763–772.
8. 8 Vogelzang, N.J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21 (2003), 2636–2644.
9. 9 Stahel, R.A., et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 16 (2015), 1651–1658.
10. 10 van Meerbeeck, J.P., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 23 (2005), 6881–6889.
11. 11 Zalcman, G., et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 387 (2016), 1405–1414.
12. 12 Roushdy-Hammady, I., et al. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357 (2001), 444–445.
13. 13 Testa, J.R., et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43 (2011), 1022–1025.
14. 14 Carbone, M., et al. BAP1 and cancer. Nat. Rev. Cancer 13 (2013), 153–159.
15. 15 Wiesner, T., et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43 (2011), 1018–1021.
16. 16 Carbone, M., et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J. Transl. Med., 10, 2012, 179.
17. 17 de la Fouchardiere, A., et al. Germline BAP1 mutations predispose also to multiple basal cell carcinomas. Clin. Genet. 88 (2015), 273–277.
18. 18 Wadt, K.A., et al. A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin. Genet. 88 (2015), 267–272.
19. 19 Farley, M.N., et al. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol. Cancer Res. 11 (2013), 1061–1071.
20. 20 Popova, T., et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am. J. Hum. Genet. 92 (2013), 974–980.
21. 21 Baumann, F., et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36 (2015), 76–81.
22. 22 Napolitano, A., et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 35 (2016), 1996–2002.
23. 23 Xu, J., et al. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res. 74 (2014), 4388–4397.
24. 24 Kadariya, Y., et al. Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res. 76 (2016), 2836–2844.
25. 25 Sneddon, S., et al. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. Gene 563 (2015), 103–105.
26. 26 Rusch, A., et al. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases. Lung Cancer 87 (2015), 77–79.
27. 27 Carbone, M., et al. Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s. PLoS Genet., 11, 2015, e1005633.
28. 28 Bott, M., et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 43 (2011), 668–672.
29. 29 Nasu, M., et al. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J. Thorac. Oncol. 10 (2015), 565–576.
30. 30 Yoshikawa, Y., et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 103 (2012), 868–874.
31. 31 Guo, G., et al. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 75 (2015), 264–269.
32. 32 Ugurluer, G., et al. Genome-based Mutational Analysis by Next Generation Sequencing in Patients with Malignant Pleural and Peritoneal Mesothelioma. Anticancer Res. 36 (2016), 2331–2338.
33. 33 Lo Iacono, M., et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J. Thorac. Oncol. 10 (2015), 492–499.
34. 34 Bueno, R., et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48 (2016), 407–416.
35. 35 de Reynies, A., et al. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin. Cancer Res. 20 (2014), 1323–1334.
36. 36 Scheuermann, J.C., et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465 (2010), 243–247.
37. 37 Sacco, J.J., et al. Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors. Oncotarget 6 (2015), 13757–13771.
38. 38 LaFave, L.M., et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat. Med. 21 (2015), 1344–1349.
39. 39 Petrilli, A.M., Fernandez-Valle, C., Role of Merlin/NF2 inactivation in tumor biology. Oncogene 35 (2016), 537–548.
40. 40 Lopez-Lago, M.A., et al. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol. Cell. Biol. 29 (2009), 4235–4249.
41. 41 Shapiro, I.M., et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci. Transl. Med., 6, 2014, 237ra68.
42. 42 Poulikakos, P.I., et al. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 25 (2006), 5960–5968.
43. 43 Li, W., et al. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. Cancer Cell 26 (2014), 48–60.
44. 44 Striedinger, K., et al. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia 10 (2008), 1204–1212.
45. 45 Ammoun, S., et al. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours. Mol. Oncol. 9 (2015), 236–248.
46. 46 Yang, H., et al. Aspirin delays mesothelioma growth by inhibiting HMGB1-mediated tumor progression. Cell Death Dis., 6, 2015, e1786.
47. 47 Hassan, R., et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin. Cancer Res. 20 (2014), 5927–5936.
48. 48 Hoffmann, P.R., et al. Preclinical development of HIvax: human survivin highly immunogenic vaccines. Hum. Vaccin. Immunother. 11 (2015), 1585–1595.
49. 49 Li, H., et al. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 17 (2010), 550–558.
50. 50 Arrowsmith, J., Trial watch: phase III and submission failures: 2007-2010. Nat. Rev. Drug Discov., 10, 2011, 87.
51. 51 Krug, L.M., et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 16 (2015), 447–456.
52. 52 Calabro, L., et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir. Med. 3 (2015), 301–309.
53. 53 AstraZeneca, AstraZeneca Reports Top-Line Result of Tremelimumab Monotherapy Trial in Mesothelioma, AstraZeneca. 2016.
54. 54 Blyth, K.G., Inconsistent results or inconsistent methods?. A plea for standardisation of biomarker sampling in mesothelioma studies. Thorax, 70, 2015, 374.
55. 55 Comertpay, S., et al. Evaluation of clonal origin of malignant mesothelioma. J. Transl. Med., 12, 2014, 301.
56. 56 Paolicchi, E., et al. Targeting hypoxic response for cancer therapy. Oncotarget 7 (2016), 13464–13478.
57. 57 Baumann, F., et al. Asbestos is not just asbestos: an unrecognised health hazard. Lancet Oncol. 14 (2013), 576–578.
58. 58 Oxford Dictionaries. Shorter Oxford English Dictionary. 5th edn, 2002, Oxford University Press.
59. 59 Pliny the Elder (AD 77) Natural History.
60. 60 Nagai, H., et al. Diameter and rigidity of multiwalled carbon nanotubes are critical factors in mesothelial injury and carcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 108 (2011), E1330–E1338.
61. 61 Carbone, M., et al. Simian virus 40: the link with human malignant mesothelioma is well established. Anticancer Res. 20 (2000), 875–877.
62. 62 Gazdar, A.F., Carbone, M., Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin. Lung Cancer 5 (2003), 177–181.
63. 63 Comar, M., et al. Increased levels of C-C chemokine RANTES in asbestos exposed workers and in malignant mesothelioma patients from an hyperendemic area. PLoS ONE, 9, 2014, e104848.
64. 64 Xu, J., et al. Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: a patient-based study. Cancer Sci. 106 (2015), 825–832.
65. 65 Amati, M., et al. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol. Biomarkers Prev. 17 (2008), 163–170.
66. 66 Amati, M., et al. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat. Res. 655 (2008), 52–58.
67. 67 Marczynski, B., et al. Levels of 8-hydroxy-2′-deoxyguanosine in DNA of white blood cells from workers highly exposed to asbestos in Germany. Mutat. Res. 468 (2000), 195–202.
68. 68 Rostila, A., et al. Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure. Lung Cancer 77 (2012), 450–459.
69. 69 Demir, M., et al. Evaluation of new biomarkers in the prediction of malignant mesothelioma in subjects with environmental asbestos exposure. Lung 194 (2016), 409–417.
70. 70 Hollevoet, K., et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J. Clin. Oncol. 30 (2012), 1541–1549.
71. 71 Cui, A., et al. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open, 4, 2014, e004145.
72. 72 Lin, H., et al. Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis. Int. J. Clin. Exp. Med. 7 (2014), 1289–1296.
73. 73 Pass, H.I., et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N. Engl. J. Med. 367 (2012), 1417–1427.
74. 74 Creaney, J., et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax 69 (2014), 895–902.
75. 75 Napolitano, A., et al. HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res., 2016, 2016.
76. 76 Morre, D.J., et al. ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms. Clin. Proteomics, 13, 2016, 2.